Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)‘s stock had its “hold” rating reaffirmed by equities researchers at Oppenheimer Holdings, Inc. in a research note issued to investors on Friday.

Several other brokerages also recently issued reports on ZYNE. Maxim Group set a $32.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, June 26th. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Cantor Fitzgerald set a $28.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, June 8th. Finally, Roth Capital set a $30.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $14.33.

Zynerba Pharmaceuticals (NASDAQ ZYNE) opened at 8.36 on Friday. Zynerba Pharmaceuticals has a 52-week low of $6.10 and a 52-week high of $23.57. The company’s market cap is $110.83 million. The firm’s 50 day moving average is $6.28 and its 200 day moving average is $6.28.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Analysts forecast that Zynerba Pharmaceuticals will post ($2.39) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Oppenheimer Holdings, Inc. Reiterates “Hold” Rating for Zynerba Pharmaceuticals, Inc. (ZYNE)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/oppenheimer-holdings-inc-reiterates-hold-rating-for-zynerba-pharmaceuticals-inc-zyne/1600696.html.

Institutional investors have recently modified their holdings of the stock. Morgan Stanley lifted its position in Zynerba Pharmaceuticals by 220.3% during the first quarter. Morgan Stanley now owns 57,752 shares of the company’s stock valued at $1,161,000 after purchasing an additional 39,722 shares during the period. Vanguard Group Inc. lifted its position in Zynerba Pharmaceuticals by 53.9% during the first quarter. Vanguard Group Inc. now owns 425,811 shares of the company’s stock valued at $8,559,000 after purchasing an additional 149,094 shares during the period. SG Americas Securities LLC bought a new position in Zynerba Pharmaceuticals during the first quarter valued at approximately $188,000. Citigroup Inc. lifted its position in Zynerba Pharmaceuticals by 13,501.1% during the second quarter. Citigroup Inc. now owns 221,698 shares of the company’s stock valued at $3,762,000 after purchasing an additional 220,068 shares during the period. Finally, Geode Capital Management LLC lifted its position in Zynerba Pharmaceuticals by 57.6% during the first quarter. Geode Capital Management LLC now owns 76,015 shares of the company’s stock valued at $1,527,000 after purchasing an additional 27,789 shares during the period. Institutional investors own 34.32% of the company’s stock.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.